Abstract
Serum angiotensin-converting enzyme (SACE) was analysed in 27 patients with Hodgkin's disease, 25 with non-Hodgkin lymphoma, 14 with acute leukaemia, 15 with chronic leukaemia, and 15 with multiple myeloma. SACE was depressed in these patients as a whole, with a mean level of 19.9 mu/ml, compared with 116 healthy controls (mean 24.4 mu/ml, P < 0.001). This depression was greatest in chronic leukaemia and multiple myeloma. In Hodgkin's disease no relationship was found between enzyme activity and stage, activity, histopathology, treatment, mediastinal involvement or prognosis. In non-Hodgkin patients a poor prognosis was generally associated with low SACE activity. The low SACE activity was not related to recent corticosteroid treatment, and the cause and pathophysiological significance is unexplained. Since SACE is high in the granulomatous disorder sarcoidosis (which can mimic malignant lymphnode and blood diseases) SACE analysis can be valuable in evaluating patients with mediastinal lymphadenopathy and those in whom non-caseating epitheliod granulomas are found.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Rømer, F., Emmertsen, K. Serum angiotensin-converting enzyme in malignant lymphomas, leukaemia and multiple myeloma. Br J Cancer 42, 314–318 (1980). https://doi.org/10.1038/bjc.1980.232
Issue Date:
DOI: https://doi.org/10.1038/bjc.1980.232
This article is cited by
-
Noninvasive testing of asymptomatic bilateral hilar adenopathy
Journal of General Internal Medicine (1990)
-
Serum enzyme concentrations in untreated acute myeloid leukaemia
Blut (1986)
-
Angiotensin-Converting-Enzym-Aktivit�t w�hrend zytostatischer Therapie bei Patienten mit prim�r inoperablem Bronchialkarzinom
Klinische Wochenschrift (1983)